IWATE MEDICAL UNIVERSITY HOSPITAL

Enfortumab Vedotin Shows Varied Efficacy Across Primary and Metastatic Urothelial Carcinoma Sites

- A recent study evaluating enfortumab vedotin (EV) in metastatic urothelial carcinoma (UC) shows varied tumor shrinkage rates between primary and metastatic sites. - Lung and lymph node metastases demonstrated more durable responses to EV compared to primary tumors, which showed shorter regrowth periods. - The real-world study reported a PFS of 7.7 months, ORR of 44%, and DCR of 85%, underscoring EV's effectiveness in advanced UC treatment. - Findings suggest combining EV with local treatments may enhance long-term disease control, especially in primary tumor sites.